Tuukka MSc - Orion Oyj Investor Officer
| ORINFDelisted Stock | USD 38.38 0.00 0.00% |
Insider
Tuukka MSc is Investor Officer of Orion Oyj
| Phone | 358 10 4261 |
| Web | https://www.orion.fi |
Orion Oyj Management Efficiency
The company has return on total asset (ROA) of 0.2077 % which means that it generated a profit of $0.2077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4065 %, meaning that it generated $0.4065 on every $100 dollars invested by stockholders. Orion Oyj's management efficiency ratios could be used to measure how well Orion Oyj manages its routine affairs as well as how well it operates its assets and liabilities.Orion Oyj has accumulated 100 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Orion Oyj has a current ratio of 3.83, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orion Oyj until it has trouble settling it off, either with new capital or with free cash flow. So, Orion Oyj's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orion Oyj sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orion to invest in growth at high rates of return. When we think about Orion Oyj's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Paul Penepent | Novartis AG ADR | N/A | |
| Charlotte Wieser | Novartis AG ADR | N/A | |
| Diane Wilfong | Gilead Sciences | 62 | |
| Shobie Ramakrishnan | GlaxoSmithKline PLC ADR | 53 | |
| Victor Bulto | Novartis AG ADR | 46 | |
| Karen Hale | Novartis AG ADR | 56 | |
| Stephen Mayo | Merck Company | 59 | |
| Deepak Khanna | Merck Company | N/A | |
| David Williams | Merck Company | 55 | |
| Jonathan Symonds | GlaxoSmithKline PLC ADR | 62 | |
| Julie Brown | GlaxoSmithKline PLC ADR | 62 | |
| Jennifer Mauer | Merck Company | N/A | |
| Robert PharmD | Novartis AG ADR | 56 | |
| Michael Quigley | Gilead Sciences | N/A | |
| Jannie Oosthuizen | Merck Company | 53 | |
| Tony Wood | GlaxoSmithKline PLC ADR | N/A | |
| Michael Klobuchar | Merck Company | 45 | |
| Dean Li | Merck Company | 58 | |
| Diana Conrad | GlaxoSmithKline PLC ADR | N/A | |
| Michael Fleming | Merck Company | 61 | |
| Samir MD | Novartis AG ADR | 62 | |
Management Performance
| Return On Equity | 0.41 | |||
| Return On Asset | 0.21 |
Orion Oyj Leadership Team
Elected by the shareholders, the Orion Oyj's board of directors comprises two types of representatives: Orion Oyj inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orion. The board's role is to monitor Orion Oyj's management team and ensure that shareholders' interests are well served. Orion Oyj's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orion Oyj's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Terhi Ormio, VP Communications | ||
| Liisa Hurme, Senior Vice President Specialty Products and Fermion; Member of the Executive Management Board | ||
| MBA M, Sr Board | ||
| Juhani Kankaanpaa, Sr Board | ||
| Olli LlM, Gen Functions | ||
| Tuukka MSc, Investor Officer | ||
| Timo Lappalainen, President CEO, Chairman of the Executive Management Board | ||
| Pr MD, Sr Board | ||
| MSc MSc, Sr Board |
Orion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Orion Oyj a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.41 | |||
| Return On Asset | 0.21 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 7.3 B | |||
| Shares Outstanding | 106.17 M | |||
| Shares Owned By Insiders | 3.44 % | |||
| Shares Owned By Institutions | 39.44 % | |||
| Price To Earning | 26.86 X | |||
| Price To Book | 8.34 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Orion Pink Sheet
If you are still planning to invest in Orion Oyj check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orion Oyj's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |